An Optional Investigation of Biomarkers of Efficacy in TH002 Clinical Study Subjects.
Phase of Trial: Phase II
Latest Information Update: 22 Apr 2015
Price : $35 *
At a glance
- Drugs HDM SPIRE (Primary)
- Indications Allergic rhinoconjunctivitis
- Focus Biomarker; Pharmacodynamics
- Sponsors Circassia
- 20 May 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 21 Jan 2014 According to ClinicalTrials.gov record study status changed from not yet recruiting to recruiting.
- 28 Sep 2013 New trial record